ArticleHereditas2025
Overexpression of miR-671-3p alleviates postmenopausal osteoporosis by targeting GREM2 to activate BMP2/SMAD signaling pathway.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic value of LncRNA JPX in osteoporotic fracture (OPF) and its role in inhibiting osteogenic differentiation by targeting miR-219a-5p.Hereditas · 2026Article
- The functional mechanism and clinical significance of miR-3651 in the healing process of Pilon fractures.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIncreased fracture risk is linked to postmenopausal osteoporosis (PMOP), and elucidating the function of microRNAs (miRNAs) in this condition is vital for identifying individuals at high risk of fractures. This research focused on exploring the function and mechanism of miR-671-3p in PMOP.
methodsUsing qRT-PCR, we measured the expression levels of miR-671-3p in the serum of PMOP patients and evaluated its predictive capacity for osteoporosis occurrence through Receiver Operating Characteristic (ROC) analysis. An in vitro model of MC3T3-E1 osteoblasts cultured under simulated microgravity (MG) was established to mimic the osteoporosis-related bone loss microenvironment. It was used to investigate miR-671-3p's regulatory effects on cell proliferation (CCK-8 assay), apoptosis (Annexin V/PI staining), and osteogenic differentiation (ALP activity and osteogenic marker mRNA levels). Dual luciferase reporter gene assays and RNA immunoprecipitation (RIP) experiments were performed to validate the interaction between miR-671-3p and GREM2.
resultsmiR-671-3p expression was reduced in PMOP patients and in MG-exposed MC3T3-E1 cells. miR-671-3p exhibited strong predictive power for early detection of PMOP. When miR-671-3p was overexpressed, it enhanced osteogenic differentiation and suppressed apoptosis in MC3T3-E1 cells. GREM2 was pinpointed as a target of miR-671-3p, which inhibited osteogenic differentiation in MC3T3-E1 cells and accelerated MG-induced apoptosis. By inhibiting GREM2 expression, overexpression of miR-671-3p activated the BMP2/SMAD signaling pathway.
conclusionReduced miR-671-3p expression may signal the presence of PMOP. By targeting GREM2 to activate the BMP2/SMAD pathway, miR-671-3p may stimulate osteogenic differentiation, foster bone formation, and prevent the onset of osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.